🔗 Share this article

Given that the United States undertakes unprecedented changes to its vaccine recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by questioning coronavirus shots throughout the pandemic and has zeroed in on possible deaths after COVID-19 vaccination in her brief tenure at the FDA.

Planned Changes to Pediatric Vaccine Program

Public health authorities were set to announce radical changes to the pediatric immunization program in December, bringing the US with the Danish national calendar, it is understood – a major change that would put the US out of alignment with many the global community with no evidence for improved outcomes. The announcement has been delayed until the new year.

Rather than the top vaccines chief, Høeg is set to present at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

A Shift at the FDA

The acting appointment could signify a closer partnership between the drug and vaccine branches as Høeg and Prasad strengthen their influence at the agency – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.

Høeg has frequently advocated for ending specific childhood immunization guidelines in the US so as to align more in line with the Danish model, a society with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

Høeg has no apparent background in pharmaceutical research, oversight or management, which has been customary for former leaders of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and CBER since March.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a large organization. She lacks background in industry regulation.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that former directors who ran CBER have had.”

CDER has an enormous range of responsibilities at the FDA, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the generic drug division approves numerous off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and more, and every single one need to be supervised,” she said. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a substantial leadership component to the job, which oversees more than 5,000 personnel. “It is a huge management job, if you perform it correctly,” she added.

Response and Controversial Initiatives

When asked about questions about Dr. Høeg's qualifications and whether this assignment represents greater collaboration among FDA leaders on immunizations, a representative stated that the “concerns are based on flawed premises”.

“Her resume is consistent with the functions of her position,” the official stated, pointing to the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial priority voucher program, a disputed one-day drug-approval program that allegedly concerned her predecessors. “By what process are these therapies being selected for this fast-track system? Who takes the choices?” Dr. Howard questioned. “There is a lot of secrecy happening at the FDA right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards less stringent rules of most medications, aside from shots.”

Established History on Vaccines

With vaccines, Høeg has a more established, if problematic, past, Howard said. She published a study using unverified crowd-sourced reports to estimate the frequency of myocarditis following Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the current federal leadership encompassed changing regulations for novel immunizations and halting “non-essential” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has according to sources suggested barring young men from receiving Covid vaccines.

“She is an all-around ideologue who begins with her preconceived notions and tailors the evidence to accommodate the data in a extremely misleading, fraudulent manner,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg joined other contrarians, {like|